Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
6
2
2024
Statut:
ppublish
Résumé
Oral Immunotherapy for Peanut Allergy in ChildrenThis trial enrolled children 1 to <4 years of age who had allergic symptoms from peanut protein during screening. Participants received peanut allergen powder-dnfp (PTAH) or placebo for approximately 12 months; 73.5% of participants receiving PTAH tolerated a single dose of ≥600 mg peanut protein versus 6.3% of the placebo group.
Identifiants
pubmed: 38320526
doi: 10.1056/EVIDoa2300145
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM